Interaction potential of the endothelin: a receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro
Atrasentan is a highly potent and selective endothelin receptor A (ETA) antagonist under development for the treatment of prostate cancer. Only little data exist on its interaction with drug-metabolising enzymes and drug transporters possibly influencing its safety and effectiveness. Our study evalu...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
31 July 2011
|
| In: |
Cancer chemotherapy and pharmacology
Year: 2011, Jahrgang: 68, Heft: 4, Pages: 1093-1098 |
| ISSN: | 1432-0843 |
| DOI: | 10.1007/s00280-011-1715-8 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00280-011-1715-8
|
| Verfasserangaben: | Johanna Weiss, Walter Emil Haefeli |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1822873096 | ||
| 003 | DE-627 | ||
| 005 | 20230710101956.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221118s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00280-011-1715-8 |2 doi | |
| 035 | |a (DE-627)1822873096 | ||
| 035 | |a (DE-599)KXP1822873096 | ||
| 035 | |a (OCoLC)1389748779 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Weiß, Johanna |e VerfasserIn |0 (DE-588)1050230906 |0 (DE-627)783666322 |0 (DE-576)404441114 |4 aut | |
| 245 | 1 | 0 | |a Interaction potential of the endothelin |b a receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro |c Johanna Weiss, Walter Emil Haefeli |
| 264 | 1 | |c 31 July 2011 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.11.2022 | ||
| 520 | |a Atrasentan is a highly potent and selective endothelin receptor A (ETA) antagonist under development for the treatment of prostate cancer. Only little data exist on its interaction with drug-metabolising enzymes and drug transporters possibly influencing its safety and effectiveness. Our study evaluated whether atrasentan can induce the expression of relevant human drug transporters and cytochrome P450 isozymes (CYPs), whether it retains its efficiency in multidrug resistant cell lines, and whether it inhibits P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). | ||
| 650 | 4 | |a Atrasentan | |
| 650 | 4 | |a CYPs | |
| 650 | 4 | |a Drug transporters | |
| 650 | 4 | |a Drug-drug interaction | |
| 650 | 4 | |a Endothelin receptor A antagonist | |
| 650 | 4 | |a Induction | |
| 700 | 1 | |a Haefeli, Walter E. |d 1958- |e VerfasserIn |0 (DE-588)124572359 |0 (DE-627)656806141 |0 (DE-576)340514221 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer chemotherapy and pharmacology |d Berlin : Springer, 1978 |g 68(2011), 4, Seite 1093-1098 |h Online-Ressource |w (DE-627)253390435 |w (DE-600)1458488-8 |w (DE-576)072283467 |x 1432-0843 |7 nnas |a Interaction potential of the endothelin a receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro |
| 773 | 1 | 8 | |g volume:68 |g year:2011 |g number:4 |g pages:1093-1098 |g extent:6 |a Interaction potential of the endothelin a receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00280-011-1715-8 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221118 | ||
| 993 | |a Editorial | ||
| 994 | |a 2011 | ||
| 998 | |g 124572359 |a Haefeli, Walter E. |m 124572359:Haefeli, Walter E. |d 910000 |d 910100 |e 910000PH124572359 |e 910100PH124572359 |k 0/910000/ |k 1/910000/910100/ |p 2 |y j | ||
| 998 | |g 1050230906 |a Weiß, Johanna |m 1050230906:Weiß, Johanna |d 910000 |d 910100 |d 50000 |e 910000PW1050230906 |e 910100PW1050230906 |e 50000PW1050230906 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1822873096 |e 4214532139 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1822873096"],"doi":["10.1007/s00280-011-1715-8"]},"name":{"displayForm":["Johanna Weiss, Walter Emil Haefeli"]},"physDesc":[{"extent":"6 S."}],"origin":[{"dateIssuedKey":"2011","dateIssuedDisp":"31 July 2011"}],"relHost":[{"title":[{"title_sort":"Cancer chemotherapy and pharmacology","title":"Cancer chemotherapy and pharmacology","subtitle":"CCP"}],"origin":[{"publisherPlace":"Berlin ; Heidelberg","dateIssuedKey":"1978","publisher":"Springer","dateIssuedDisp":"1978-"}],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Interaction potential of the endothelin a receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitroCancer chemotherapy and pharmacology","language":["eng"],"id":{"zdb":["1458488-8"],"eki":["253390435"],"issn":["1432-0843"]},"titleAlt":[{"title":"CCP"}],"part":{"text":"68(2011), 4, Seite 1093-1098","extent":"6","year":"2011","pages":"1093-1098","volume":"68","issue":"4"},"recId":"253390435","note":["Gesehen am 02.12.05","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 38.1996: Supplement"],"pubHistory":["1.1978 -"],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"person":[{"family":"Weiß","display":"Weiß, Johanna","role":"aut","roleDisplay":"VerfasserIn","given":"Johanna"},{"display":"Haefeli, Walter E.","given":"Walter E.","role":"aut","roleDisplay":"VerfasserIn","family":"Haefeli"}],"language":["eng"],"title":[{"subtitle":"a receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro","title":"Interaction potential of the endothelin","title_sort":"Interaction potential of the endothelin"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 18.11.2022"],"recId":"1822873096"} | ||
| SRT | |a WEISSJOHANINTERACTIO3120 | ||